ANIK
Price
$9.51
Change
-$0.16 (-1.65%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
139.45M
111 days until earnings call
Intraday BUY SELL Signals
ASRT
Price
$0.75
Change
-$0.00 (-0.00%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
72.55M
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANIK vs ASRT

Header iconANIK vs ASRT Comparison
Open Charts ANIK vs ASRTBanner chart's image
Anika Therapeutics
Price$9.51
Change-$0.16 (-1.65%)
Volume$6.32K
Capitalization139.45M
Assertio Holdings
Price$0.75
Change-$0.00 (-0.00%)
Volume$1.9K
Capitalization72.55M
ANIK vs ASRT Comparison Chart in %
ANIK
Daily Signal:
Gain/Loss:
ASRT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ANIK vs. ASRT commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a Hold and ASRT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ANIK: $9.67 vs. ASRT: $0.75)
Brand notoriety: ANIK and ASRT are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ANIK: 123% vs. ASRT: 120%
Market capitalization -- ANIK: $137.29M vs. ASRT: $72.55M
ANIK [@Pharmaceuticals: Generic] is valued at $137.29M. ASRT’s [@Pharmaceuticals: Generic] market capitalization is $72.55M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIK’s FA Score shows that 0 FA rating(s) are green whileASRT’s FA Score has 0 green FA rating(s).

  • ANIK’s FA Score: 0 green, 5 red.
  • ASRT’s FA Score: 0 green, 5 red.
According to our system of comparison, both ANIK and ASRT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIK’s TA Score shows that 4 TA indicator(s) are bullish while ASRT’s TA Score has 3 bullish TA indicator(s).

  • ANIK’s TA Score: 4 bullish, 4 bearish.
  • ASRT’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ANIK is a better buy in the short-term than ASRT.

Price Growth

ANIK (@Pharmaceuticals: Generic) experienced а -4.54% price change this week, while ASRT (@Pharmaceuticals: Generic) price change was -18.80% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.77%. For the same industry, the average monthly price growth was -6.55%, and the average quarterly price growth was +28.28%.

Reported Earning Dates

ANIK is expected to report earnings on Mar 10, 2026.

ASRT is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.77% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANIK($139M) has a higher market cap than ASRT($72.6M). ASRT YTD gains are higher at: -14.212 vs. ANIK (-41.252). ANIK has higher annual earnings (EBITDA): -2.24M vs. ASRT (-8.66M). ASRT has more cash in the bank: 98.2M vs. ANIK (53.2M). ANIK has less debt than ASRT: ANIK (25M) vs ASRT (39.9M). ASRT (117M) and ANIK (115M) have equivalent revenues.
ANIKASRTANIK / ASRT
Capitalization139M72.6M191%
EBITDA-2.24M-8.66M26%
Gain YTD-41.252-14.212290%
P/E Ratio10.71N/A-
Revenue115M117M98%
Total Cash53.2M98.2M54%
Total Debt25M39.9M63%
FUNDAMENTALS RATINGS
ANIK vs ASRT: Fundamental Ratings
ANIK
ASRT
OUTLOOK RATING
1..100
8311
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
6060
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ASRT's Valuation (72) in the Pharmaceuticals Major industry is in the same range as ANIK (89) in the Pharmaceuticals Other industry. This means that ASRT’s stock grew similarly to ANIK’s over the last 12 months.

ASRT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that ASRT’s stock grew similarly to ANIK’s over the last 12 months.

ASRT's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as ANIK (95) in the Pharmaceuticals Other industry. This means that ASRT’s stock grew similarly to ANIK’s over the last 12 months.

ASRT's Price Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as ANIK (60) in the Pharmaceuticals Other industry. This means that ASRT’s stock grew similarly to ANIK’s over the last 12 months.

ASRT's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that ASRT’s stock grew similarly to ANIK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIKASRT
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
64%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
75%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ANIK
Daily Signal:
Gain/Loss:
ASRT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTRGF0.82N/A
N/A
Country Garden Svcs Hldgs Co Ltd.
IDBHF0.05N/A
N/A
Industrias Bachoco S.A.B. de C.V.
CAPFF1.55N/A
N/A
Capital Limited
LEEN0.19N/A
N/A
Leopard Energy, Inc.
RKUNF5.38-0.33
-5.78%
Rakuten Group Inc.